| 1 |
34486539 | Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed. | 2022 Jan 1 |
2 |
| 2 |
35046665 | Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study. | 2022 |
1 |
| 3 |
35093869 | A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed. | 2022 Feb |
1 |
| 4 |
35501907 | Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence. | 2022 May 3 |
3 |
| 5 |
33989780 | Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615). | 2021 Aug |
4 |
| 6 |
34181276 | Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment. | 2021 Oct 15 |
2 |
| 7 |
34303276 | Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure. | 2021 Sep |
1 |
| 8 |
34377263 | Effect of pemetrexed on the efficacy, toxic reaction, and survival rate of patients with EGFR-TKI resistant moderate and advanced lung cancer. | 2021 |
3 |
| 9 |
34490108 | GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins. | 2021 |
3 |
| 10 |
34590025 | Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report. | 2021 Jun |
1 |
| 11 |
34802094 | EGFR-targeted pemetrexed therapy of malignant pleural mesothelioma. | 2021 Nov 20 |
4 |
| 12 |
30760168 | Treatment exceeds expectations in a patient with non-small cell lung adenocarcinoma with an EGFR exon 20 mutation. | 2020 Jan |
1 |
| 13 |
31682542 | Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. | 2020 Jan 10 |
1 |
| 14 |
32170554 | Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study. | 2020 Apr |
1 |
| 15 |
32620471 | Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis. | 2020 Nov |
1 |
| 16 |
32648459 | Treatment response to intrathecal chemotherapy with pemetrexed via an Ommaya reservoir in EGFR-mutated leptomeningeal metastases from non-small cell lung cancer: a case report. | 2020 Jul |
1 |
| 17 |
32692221 | Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases. | 2020 Jul |
1 |
| 18 |
32702875 | A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC. | 2020 Jul 17 |
1 |
| 19 |
32957736 | Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. | 2020 Sep 17 |
2 |
| 20 |
33163410 | Treatment Patterns and Survival Outcomes of Non-Small Cell Lung Cancer Patients Initially Diagnosed With Brain Metastases in Real-World Clinical Practice. | 2020 |
1 |
| 21 |
33209607 | Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. | 2020 Oct |
1 |
| 22 |
30177585 | A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. | 2019 Apr |
1 |
| 23 |
30653134 | Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status. | 2019 Jan |
6 |
| 24 |
30838090 | FGF2-FGFR1 pathway activation together with thymidylate synthase upregulation is induced in pemetrexed-resistant lung cancer cells. | 2019 Feb 5 |
1 |
| 25 |
30953548 | Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo. | 2019 Apr 5 |
1 |
| 26 |
31010639 | Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer. | 2019 Jul |
3 |
| 27 |
31138260 | Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. | 2019 May 28 |
2 |
| 28 |
31319622 | Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer. | 2019 Jul 17 |
2 |
| 29 |
31450915 | Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. | 2019 Aug 1 |
1 |
| 30 |
31591158 | Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. | 2019 Oct 7 |
1 |
| 31 |
31791326 | Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. | 2019 Dec 2 |
1 |
| 32 |
31795298 | Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. | 2019 Nov 28 |
2 |
| 33 |
28743421 | A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. | 2018 Jan |
4 |
| 34 |
29101518 | Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations. | 2018 Aug |
1 |
| 35 |
29527843 | Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis. | 2018 Apr |
2 |
| 36 |
29531840 | Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. | 2018 |
2 |
| 37 |
29644460 | Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer. | 2018 Jun |
2 |
| 38 |
29682186 | Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer. | 2018 Mar 30 |
2 |
| 39 |
29695919 | Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. | 2018 |
5 |
| 40 |
29983578 | Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis. | 2018 |
1 |
| 41 |
30027464 | A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101). | 2018 Dec |
1 |
| 42 |
30027579 | Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors. | 2018 Sep |
1 |
| 43 |
30047610 | Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts. | 2018 Sep |
1 |
| 44 |
30061238 | Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs. | 2018 Aug |
2 |
| 45 |
30067451 | Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report. | 2018 |
1 |
| 46 |
30089597 | Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506). | 2018 Sep |
3 |
| 47 |
30268482 | Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations. | 2018 Oct |
2 |
| 48 |
27575422 | High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer. | 2017 Jan |
1 |
| 49 |
27918713 | Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. | 2017 Feb 20 |
1 |
| 50 |
27919627 | Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. | 2017 Jan |
2 |